0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FOLR1

FOLR1

FOLR1 Molecule Information

Name:Folate receptor alpha
Target Synonym:FOLR1;Folate receptor 1;FR-alpha;FOLR;Adult folate-binding protein;Folate receptor, adult;Folate receptor alpha;KB cells FBP;Ovarian tumor-associated antigen MOv18;FBP
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:15
Lastest Research Phase:Phase ?

FOLR1 Protein Product ListCompare or Buy

FOLR1 Molecule Synonym Name

FOLR-1,FBP,FOLR

FOLR1 Molecule Background

Folate Receptor 1 (FOLR1) is also known as Folate receptor alpha, Folate Binding Protein (FBP), FOLR, and is a member of the folate receptor (FOLR) family. Members of this gene family have a high affinity for folic acid and for several reduced folic acid derivatives, and mediate delivery of 5-methyltetrahydrofolate to the interior of cells. Mature FOLR1 is an N-glycosylated protein that is anchored to the cell surface by a GPI linkage. FOLR1 is predominantly expressed on epithelial cells and is dramatically upregulated on many carcinomas. FOLR1 is internalized to the endosomal system where it dissociates from its ligand before recycling to the cell surface. A soluble form of FOLR1 can be proteolytically shed from the cell surface into the serum and breast milk. Defects in FOLR1 are the cause of neurodegeneration due to cerebral folate transport deficiency (NCFTD). NCFTD is an autosomal recessive disorder resulting from brain-specific folate deficiency early in life.

FOLR1 References

FOLR1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
GALE-302 GALE-302; E-39; J-65 Phase Ⅱ Galena Biopharma Breast cancer, Ovarian cancer Details
OCTR lymphocytes (Centocor) Phase Ⅱ Johnson & Johnson Ovarian cancer Details
MOv18 IgE (King's College London) Phase Ⅰ King's College London, Cancer Research UK Cancer Details
Vintafolide MK-8109; EC-145 Phase Ⅱ Novartis, Merck Sharp & Dohme Non small cell lung cancer (NSCLC) Details
EC-1456 EC-1456; EC-0531 Phase Ⅰ Novartis Non small cell lung cancer (NSCLC), Ovarian cancer Details
Mirvetuximab soravtansine IMGN-853; M9346-Asulfo-SPDB-DM4,IMGN853; M-9346-Asulfo-SPDB-DM4 Phase Ⅲ ImmunoGen Fallopian tube cancer, Endometrial cancer, Breast cancer, Solid tumours, Peritoneum cancer, Ovarian cancer Details
EC-0905 EC-0905 Preclinical Novartis Cancer Details
MORAb-202 MORAb-202,MORAb202; MORAb 202 Phase Ⅰ Morphotek Solid tumours Details
OTL-38 OTL-38; OTL-0038; Pteroyl-L-Tyr-S0456; EC-17 Phase Ⅲ On Target Ovarian cancer Details
Epofolate BMS-753493 Phase Ⅱ Bristol-Myers Squibb, Novartis Solid tumours Details
Anti-CD3-anti-MOv18 monoclonal antibody Phase Ⅱ Centocor Ovarian cancer Details
NMI-500 Phase Ⅰ Nemucore Medical Innovations Breast cancer, Ovarian cancer Details
EC-0305 EC-0305; F-0305 Phase Ⅰ Novartis Solid tumours Details
Noscapine-folate conjugate Phase Ⅰ Emory University Immune-inflammatory diseases, Solid tumours, Hematological cancer Details
Farletuzumab MORAb-003,MORAb003 Phase Ⅲ Morphotek Ovarian cancer Details

This web search service is supported by Google Inc.

totop